Amgen Inc (AMGN) Stock Price, Quote & News

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 805 447 1000

Fax: 805 447 1010

Website: www.amgen.com

Address:

One Amgen Center Drive, Thousand Oaks, United States

BioTechHealthX Jul. 4 at 12:45 PM

$ALNY $AMGN $BNTX $GILD $MRNA From GLP-1 obesity drugs to mRNA cancer therapies and rare disease treatments, these 10 biotech and biopharma stocks are linked to some of the strongest innovation trends reshaping medicine and Wall Street. https://biotechhealthx.com/biotech-news/10-biotech-stocks-that-could-turn-medicine-into-wall-streets-next-gold-rush/

0 · Reply

kshonstocks Jul. 3 at 3:55 PM

$AMGN chart is v pretty

0 · Reply

DanteValerian Jul. 2 at 6:27 PM

The unwinding of the single most crowded speculative sector trade of the past 30 years has begun, as expected. The smart money has been moving into Biotech and Cyclical assets - which is where we've been positioning for the past three+ weeks. Now it's payday. $XBI $AMGN $AAPL $MO

1 · Reply

DanteValerian Jul. 2 at 4:39 PM

$MU Well, there she goes 💣 As expected, $MU's pain was $AMGN's gain. Do you know why? Financial Industry Insiders do.

0 · Reply

oceanbleu Jul. 2 at 4:28 PM

$AMGN slowly moving to the retest of 388$ and likely gets above but I still plan to take partial profit at 388 from the last add at 329$. There is clean accumulation on daily in 325/345 area. Plenty of catalyst for AMGN in Q3/Q4.

0 · Reply

DanteValerian Jul. 2 at 2:54 PM

$AMGN is delivering +400% on the Call options with absolutely zero hassle or drawdown from the Buy Signal Arc's entry plan posted on June 16th: https://www.tradingview.com/chart/AMGN/bU2Zv0eK-AMGN-completed-a-Buy-Signal-Arc/ 💰We'll be counting our profits while enjoying the fireworks this 4th of July. Congrats to all members!

0 · Reply

DefenseMania Jul. 2 at 2:39 PM

$ABBV $GILD $AMGN $$PFE looks like it’s biotech time for the next bull run !!!!

0 · Reply

MAFFHEW_MCCONAGHEY Jul. 2 at 1:49 PM

$AMGN @Kosmos709 👀

2 · Reply

howardlindzon Jun. 30 at 8:15 PM

$AMGN ideas …

0 · Reply

BioGypsy Jun. 30 at 3:06 PM

$CRDF $PFE $AMGN $XBI Retail needs to wake up quickly and help CRDF out. Acquisition is coming IMO and the setup is incredible. Let’s Go Start accumulating a position now!

1 · Reply

Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel

Jun 29, 2026, 4:46 PM EDT - 4 days ago

Medical journal retracts paper on Amgen's Tavneos drug trial after FDA findings

2026-06-29T19:30:10.000Z - 4 days ago

Trial used to approve Amgen’s Tavneos retracted from NEJM

Jun 26, 2026, 8:26 AM EDT - 8 days ago

European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked

Jun 26, 2026, 7:10 AM EDT - 8 days ago

EMA recommends revoking marketing authorisation for Amgen's rare-disease drug

2026-06-25T10:25:10.000Z - 9 days ago

FDA works to pull Amgen’s Tavneos off the market, Bloomberg says

Jun 17, 2026, 12:30 PM EDT - 17 days ago

The Healthcare M&A Wave

ABT ALNY AMRX ANTX AZN BDX BEAM

2026-06-16T11:15:43.000Z - 18 days ago

Amgen price target raised to $303 from $295 at Mizuho

Jun 14, 2026, 8:01 PM EDT - 19 days ago

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

Jun 13, 2026, 8:00 AM EDT - 21 days ago

Drugmakers race to find a place in the next wave of obesity drugs

NVO AZN LLY

Jun 11, 2026, 7:28 PM EDT - 22 days ago

Amgen taps research firm to reassess Tavneos data

Jun 11, 2026, 7:14 AM EDT - 23 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS GILD IBB IHE JNJ KYMR

2026-06-10T12:00:44.000Z - 24 days ago

Amgen price target raised to $340 from $332 at Morgan Stanley

Jun 9, 2026, 9:20 AM EDT - 25 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

JNJ LLY MRK NVO PFE

Jun 9, 2026, 9:20 AM EDT - 25 days ago

Amgen Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-07T22:20:33.000Z - 26 days ago

Amgen announces data at ADA Scientific Sessions on cardiometabolic conditions

Jun 7, 2026, 4:45 PM EDT - 26 days ago

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

2026-06-05T12:55:40.000Z - 4 weeks ago

Amgen price target lowered to $389 from $425 at Goldman Sachs

Jun 4, 2026, 4:01 PM EDT - 4 weeks ago

AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

Jun 4, 2026, 9:55 AM EDT - 4 weeks ago

Amgen Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 9:00 AM EDT - 4 weeks ago

AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026

2026-06-01T20:35:14.000Z - 4 weeks ago

European Commission approves Amgen’s Imdylltra for ES-SCLC

May 29, 2026, 4:01 PM EDT - 5 weeks ago

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

May 27, 2026, 11:45 AM EDT - 5 weeks ago

This Boring Income Portfolio Strategy Could Unlock 300%+ Upside

May 27, 2026, 9:00 AM EDT - 5 weeks ago

Ember LifeSciences announces new strategic investments boosting Series A to $27M

May 21, 2026, 6:24 AM EDT - 6 weeks ago

Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths

May 19, 2026, 5:20 PM EDT - 6 weeks ago

Amgen says CFO Peter Griffith to retire, names Dittrich as successor

2026-05-19T20:13:09.000Z - 6 weeks ago

Amgen CFO Peter Griffith to retire, Thomas Dittrich to succeed

May 19, 2026, 4:05 PM EDT - 6 weeks ago

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

May 15, 2026, 4:16 PM EDT - 7 weeks ago

Amgen's rare disease drug linked to deaths, liver injuries in Japan, WSJ reports

May 15, 2026, 3:37 PM EDT - 7 weeks ago

Twenty people in Japan who took an Amgen rare immune-disease drug have died, according to the company that sells the medicine in Japan. U.S. drug regulators had asked Amgen to voluntarily withdraw the drug.

2026-05-14T11:05:39.000Z - 7 weeks ago

Amgen price target lowered to $427 from $432 at Piper Sandler

May 13, 2026, 1:00 PM EDT - 7 weeks ago

Amgen Transcript: Bank of America Global Healthcare Conference 2026

May 7, 2026, 4:01 PM EDT - 2 months ago

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

2026-05-07T12:36:50.000Z - 2 months ago

Amgen upgraded to Buy from Hold at Freedom Broker

2026-05-05T10:28:11.000Z - 2 months ago

Amgen downgraded to Hold from Buy at Erste Group

2026-05-05T10:26:09.000Z - 2 months ago

Erste downgrades Amgen on declining sales growth

2026-05-04T13:45:20.000Z - 2 months ago

Amgen to invest additional $300M in U.S. manufacturing network

May 4, 2026, 9:42 AM EDT - 2 months ago

Amgen to invest additional $300 million to boost US manufacturing footprint

May 4, 2026, 9:00 AM EDT - 2 months ago

AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR

2026-05-04T11:27:17.000Z - 2 months ago

Amgen price target lowered to $340 from $351 at Guggenheim

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Amgen Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Amgen Slides: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Amgen Earnings release: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Amgen Quarterly report: Q1 2026

Apr 30, 2026, 4:19 PM EDT - 2 months ago

Amgen Posts Higher First-Quarter Profit, Revenue

Apr 30, 2026, 4:06 PM EDT - 2 months ago

Amgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug

Apr 30, 2026, 4:01 PM EDT - 2 months ago

AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Apr 27, 2026, 9:04 PM EDT - 2 months ago

FDA proposes to withdraw Amgen's rare autoimmune disease drug

Apr 27, 2026, 12:55 PM EDT - 2 months ago

Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs

NVS LLY

Apr 24, 2026, 4:01 PM EDT - 2 months ago

AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS

Apr 22, 2026, 4:00 PM EDT - 2 months ago

AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Amgen Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 2 months ago

Amgen Proxy statement: Proxy filing

Apr 10, 2026, 4:10 AM EDT - 3 months ago

Amgen's lung cancer drug tarlatamab wins China approval

Apr 7, 2026, 2:54 PM EDT - 3 months ago

15 stocks to put on your list to buy when the market recovers

ADBE BMY CVS KNSL MS NVDA TGT

Apr 6, 2026, 12:10 PM EDT - 3 months ago

Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.

VRDN

Apr 6, 2026, 9:00 AM EDT - 3 months ago

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE

Apr 3, 2026, 11:08 AM EDT - 3 months ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

ABBV AZN BMY MRK NVO

Apr 2, 2026, 5:34 PM EDT - 3 months ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO ABBV BMY MRK

Apr 2, 2026, 5:33 PM EDT - 3 months ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

ABBV AZN BMY MRK NVO

Apr 2, 2026, 3:29 PM EDT - 3 months ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO ABBV BMY MRK

Apr 2, 2026, 2:59 PM EDT - 3 months ago

Global pharma companies that have publicly announced Trump drug pricing agreements

ABBV AZN BMY MRK

Apr 1, 2026, 7:30 AM EDT - 3 months ago

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

ZLAB

Mar 31, 2026, 11:16 AM EDT - 3 months ago

FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths

Mar 31, 2026, 11:07 AM EDT - 3 months ago

US FDA warns of liver injury cases tied to Amgen's rare disease drug

Mar 28, 2026, 4:45 PM EDT - 3 months ago

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Mar 18, 2026, 2:23 PM EDT - 3 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AZN BMY GILD GSK JNJ LLY

Mar 13, 2026, 8:27 PM EDT - 4 months ago

GSK and Amgen to add medicines to TrumpRx, Fox Business reports

GSK

Mar 11, 2026, 9:20 AM EDT - 4 months ago

Amgen Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 4:01 PM EST - 4 months ago

AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE

Mar 4, 2026, 4:01 PM EST - 4 months ago

AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

Mar 2, 2026, 1:10 PM EST - 4 months ago

Amgen Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 4:01 PM EST - 4 months ago

AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

Feb 18, 2026, 3:15 PM EST - 4 months ago

Amgen Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 13, 2026, 4:01 PM EST - 5 months ago

AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

BioTechHealthX Jul. 4 at 12:45 PM

0 · Reply

kshonstocks Jul. 3 at 3:55 PM

$AMGN chart is v pretty

0 · Reply

DanteValerian Jul. 2 at 6:27 PM

1 · Reply

DanteValerian Jul. 2 at 4:39 PM

$MU Well, there she goes 💣 As expected, $MU's pain was $AMGN's gain. Do you know why? Financial Industry Insiders do.

0 · Reply

oceanbleu Jul. 2 at 4:28 PM

0 · Reply

DanteValerian Jul. 2 at 2:54 PM

0 · Reply

DefenseMania Jul. 2 at 2:39 PM

$ABBV $GILD $AMGN $$PFE looks like it’s biotech time for the next bull run !!!!

0 · Reply

MAFFHEW_MCCONAGHEY Jul. 2 at 1:49 PM

$AMGN @Kosmos709 👀

2 · Reply

howardlindzon Jun. 30 at 8:15 PM

$AMGN ideas …

0 · Reply

BioGypsy Jun. 30 at 3:06 PM

$CRDF $PFE $AMGN $XBI Retail needs to wake up quickly and help CRDF out. Acquisition is coming IMO and the setup is incredible. Let’s Go Start accumulating a position now!

1 · Reply

DanteValerian Jun. 30 at 1:06 PM

$XBI $VRTX $AMGN Did you profit from the information that Institutional Insiders were accumulating Biotech Stocks? That has been a key focus since late May, and has paid off with precision for those who had the information and acted on it with a steady hand.

0 · Reply

James_dean117 Jun. 30 at 12:27 PM

$AMGN trying to get into this Olpasiran clinical trial right now, miracle drug / treatment. Lipoprotein a drops 95% - 98% via siRNA 1 injection every 3 months - gene silencing of the lpa gene in the liver

0 · Reply

FibonacciTrader_ Jun. 30 at 12:05 AM

STRUCTURE WATCH Watching multiple large-cap setups transitioning from base → breakout behavior. Not chasing, just tracking technical confirmation. $AMGN - bullish inverse h&s breakout, could see another $40 to the upside $BA - could be early stages of an inverse h&s with neckline around $230 $SHW - inverse h&s breakout last week, measured move towards $367 $HON - finally a consolidation break, keep an eye on $236 as new support Key theme: if these structures hold on retests, this is how multi-week trend legs begin- not from news, but from structure acceptance. Patterns confirm probability, not certainty

0 · Reply

Quantumup Jun. 29 at 4:48 PM

William Blair reiterated Viridian at an Outperform and said, We came away from the call incrementally more confident in the company's commercial readiness and the long-term opportunity for Lumvoa. $AMGN $IMVT - ROIV RHHBY TRML ALMS Wedbush⬆️ $VRDN's PT and said, Remain Outperform rated on VRDN, new $43 target. Here's what else Wedbush had to say: https://x.com/Quantumup1/status/2071636565064057133?s=20

0 · Reply

NorthStarStats Jun. 29 at 1:44 PM

Stocks we're following. Setups to study, not trade recommendations $PANW $AMGN $HON $FTNT $AEP

0 · Reply

harmongreg Jun. 29 at 1:05 PM

Dragonfly Capital - 4 Trade Ideas for Amgen: Bonus Idea $AMGN https://dragonflycap.com/4-trade-ideas-for-amgen-bonus-idea-11/

0 · Reply

Quantumup Jun. 29 at 12:49 PM

UBS reiterated $VRDN Buy-$50 and said, VRDN announced Lumvoa (previously named veligrotug) is now approved in both active and chronic TED as expected, based on positive data from both THRIVE-1 and THRIVE-2. $AMGN $IMVT - ROIV ALMS RHHBY TRML Here's what else UBS had to say: https://x.com/Quantumup1/status/2071576402843861239?s=20

0 · Reply

Quantumup Jun. 29 at 11:16 AM

Citizens reitd $VRDN Mkt OP, $35 and said: Lumvoa (veli) approved by FDA with the expected differentiated label; we reiterate our Market Outperform rating and $35 risk-adjusted, DCF-derived price target on Viridian Therapeutics. $AMGN $ALMS IMVT - ROIV RHHBY TRML Citizens added—On Friday, the FDA approved Lumvoa (veligrotug) for the treatment of thyroid eye disease ahead of its June 30, 2026 PDUFA date. As expected, the label is inclusive of positive Phase 3 results for both active and chronic TED populations. The company anticipates immediate launch of Lumvoa and created ViridianCares, a patient support program, to enable broad access of Lumvoa. We continue to believe that the company is well-prepared to execute the launch of Lumvoa.

0 · Reply

JuggernautRaider Jun. 29 at 11:03 AM

$TNXP 1) Mark Cuban is a fraud. He only knows sales. His tech is 💩 2) you should sell Shitcoin. I think it peaked at $100K but who knows 3) I’m buying more TNXP before its third and final run of the past two years 🏃‍♂️ 4) Seth Lederman needs to retire as acting CEO. The board is feckless and pathetic. How do they still have their jobs? 5) i’ll be launching my Academy “platform” under my LLC to advise on any other stocks that my subscribers want 😊 This will be a great week. I am a free agent again - which means I can use my social media skills to make Seth and Tonix look bad at their jobs, while also informing you all more freely 🆓 The sales numbers just scratch the story of launch. I believe Tonmya can be a billion dollar franchise by itself. Just like Otezla at $AMGN , formerly of $BMY . This is no Jakafi from $INCY but with the right CEO… 🤔

0 · Reply

JFDI Jun. 28 at 5:29 PM

$AMGN

0 · Reply

Night_Owl_Biotech Jun. 27 at 6:35 PM

The FDA approved $VRDN 's Lumvoa for TED yesterday. Some say it is a minimal threat to $AMGN Tepezza yet the 9 analysts who provide FY30 revenue estimates forecast $850MM to $1.8B in product revenues. VRDN pays 7.5% to DRI Healthcare. The attachment compares VRDN multiples to peer new commercial-stage non-oncology focused bios with 1st approvals over the last 12 months. Only $MESO trades at a lower multiple but there are only multiple analysts providing estimates after FY28. $CYTK & $ARWR are clearly the multiples to aspire to. The multiples may appear high but remember ACLX, NUVL & TERN. This is not investment advice as the comps may be apples to bowling balls.

2 · Reply

Hollywood_1 Jun. 27 at 5:07 AM

$AMGN 👀

0 · Reply

Market Cap	201.93B
Revenue (ttm)	36.75B
Net Income (ttm)	7.71B
EPS (ttm)	N/A
PE Ratio	16.35
Forward PE	16.14
Profit Margin	20.98%
Debt to Equity Ratio	6.24

Volume	2,487,800
Avg Vol	2,837,176
Day's Range	N/A - N/A
Shares Out	539.71M
Stochastic %K	97%
Beta	0.41
Analysts	Sell
Price Target	$357.06